BLOG

endpoints

Aphaia hits primary endpoint with oral glucose drug in mid-stage prediabetes trial

The idea behind Aphaia Pharma is to treat metabolic disease early enough that patients don’t progress to a type 2 diabetes diagnosis.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}